Literature DB >> 21953015

Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?

Kathleen E Corey, Naga Chalasani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21953015      PMCID： PMC3644213          DOI： 10.1002/hep.24696

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  11 in total

1.  A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease.

Authors:  Giovanni Musso; Roberto Gambino; Maurizio Cassader; Gianfranco Pagano
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

2.  Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial.

Authors:  Dawn M Torres; Frances J Jones; Janet C Shaw; Christopher D Williams; John A Ward; Stephen A Harrison
Journal:  Hepatology       Date:  2011-11       Impact factor: 17.425

3.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

Authors:  Arun J Sanyal; Naga Chalasani; Kris V Kowdley; Arthur McCullough; Anna Mae Diehl; Nathan M Bass; Brent A Neuschwander-Tetri; Joel E Lavine; James Tonascia; Aynur Unalp; Mark Van Natta; Jeanne Clark; Elizabeth M Brunt; David E Kleiner; Jay H Hoofnagle; Patricia R Robuck
Journal:  N Engl J Med       Date:  2010-04-28       Impact factor: 91.245

4.  Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.

Authors:  Joel E Lavine; Jeffrey B Schwimmer; Mark L Van Natta; Jean P Molleston; Karen F Murray; Philip Rosenthal; Stephanie H Abrams; Ann O Scheimann; Arun J Sanyal; Naga Chalasani; James Tonascia; Aynur Ünalp; Jeanne M Clark; Elizabeth M Brunt; David E Kleiner; Jay H Hoofnagle; Patricia R Robuck
Journal:  JAMA       Date:  2011-04-27       Impact factor: 56.272

5.  Endpoints and clinical trial design for nonalcoholic steatohepatitis.

Authors:  Arun J Sanyal; Elizabeth M Brunt; David E Kleiner; Kris V Kowdley; Naga Chalasani; Joel E Lavine; Vlad Ratziu; Arthur McCullough
Journal:  Hepatology       Date:  2011-07       Impact factor: 17.425

6.  Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CCl4 in rats.

Authors:  Yao Hong Wei; Li Jun; Chen Ji Qiang
Journal:  Dig Dis Sci       Date:  2004-10       Impact factor: 3.199

7.  Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis.

Authors:  Shiro Yokohama; Masashi Yoneda; Masakazu Haneda; Satoshi Okamoto; Mituyoshi Okada; Kazunobu Aso; Takenao Hasegawa; Yoshihiko Tokusashi; Naoyuki Miyokawa; Kimihide Nakamura
Journal:  Hepatology       Date:  2004-11       Impact factor: 17.425

8.  Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension.

Authors:  Vincent Croquet; Frédéric Moal; Nary Veal; Jianhua Wang; Frédéric Oberti; Jérôme Roux; Eric Vuillemin; Yves Gallois; Olivier Douay; Daniel Chappard; Paul Calès
Journal:  J Hepatol       Date:  2002-12       Impact factor: 25.083

9.  AT1A-deficient mice show less severe progression of liver fibrosis induced by CCl(4).

Authors:  Keishi Kanno; Susumu Tazuma; Kazuaki Chayama
Journal:  Biochem Biophys Res Commun       Date:  2003-08-15       Impact factor: 3.575

10.  Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis.

Authors:  Amalia Gastaldelli; Stephen A Harrison; Renata Belfort-Aguilar; Lou Jean Hardies; Bogdan Balas; Steven Schenker; Kenneth Cusi
Journal:  Hepatology       Date:  2009-10       Impact factor: 17.425
View more
  4 in total

Review 1.  Therapeutic pipeline in nonalcoholic steatohepatitis.

Authors:  Raj Vuppalanchi; Mazen Noureddin; Naim Alkhouri; Arun J Sanyal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-02-10       Impact factor: 46.802

2.  Protective Effects of Tiaoganquzhi Decoction in Treating inflammatory Injury of Nonalcoholic Fatty liver Disease by Promoting CGI-58 and Inhibiting Expression of NLRP3 Inflammasome.

Authors:  Huicun Zhang; Xiang Gao; Pengmin Chen; Hongbing Wang
Journal:  Front Pharmacol       Date:  2022-05-02       Impact factor: 5.988

3.  Randomized placebo-controlled trial of losartan for pediatric NAFLD.

Authors:  Miriam B Vos; Mark L Van Natta; Niviann M Blondet; Srinivasan Dasarathy; Mark Fishbein; Paula Hertel; Ajay K Jain; Saul J Karpen; Joel E Lavine; Saeed Mohammad; Laura A Miriel; Jean P Molleston; Marialena Mouzaki; Arun Sanyal; Emily P Sharkey; Jeffrey B Schwimmer; James Tonascia; Laura A Wilson; Stavra A Xanthakos
Journal:  Hepatology       Date:  2022-02-28       Impact factor: 17.298

4.  Cholesterol Accumulation as a Driver of Hepatic Inflammation Under Translational Dietary Conditions Can Be Attenuated by a Multicomponent Medicine.

Authors:  Andrea M Mueller; Robert Kleemann; Eveline Gart; Wim van Duyvenvoorde; Lars Verschuren; Martien Caspers; Aswin Menke; Natascha Krömmelbein; Kanita Salic; Yvonne Burmeister; Bernd Seilheimer; Martine C Morrison
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-18       Impact factor: 5.555
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.